Advertisement
U.S. markets open in 10 minutes

Palisade Bio, Inc. (PALI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.4290-0.0110 (-2.50%)
At close: 04:00PM EST
0.4200 -0.01 (-2.10%)
Pre-Market: 08:58AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.4400
Open0.4340
Bid0.4150 x 1800
Ask0.4300 x 1300
Day's Range0.4150 - 0.4500
52 Week Range0.4100 - 3.6500
Volume319,457
Avg. Volume2,788,451
Market Cap5.204M
Beta (5Y Monthly)1.58
PE Ratio (TTM)1.34
EPS (TTM)0.3200
Earnings DateMar 21, 2024 - Mar 25, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for PALI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Palisade Bio, Inc.
    Daily – Vickers Top Insider Picks for 11/16/2021The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    2 years agoArgus Research
View more
  • GlobeNewswire

    Palisade Bio to Present at Digestive Disease Week (DDW) 2024

    Carlsbad, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced that its abstract has been accepted for poster presentation at DDW 2024 being held in Washington, D.C., May 18-21, 2024. The details of the poster presentation are as follows: Title: LOCAL BIOACTIVATION AND EFFICACY OF PALI-2108: A PROMISING PDE4 INH

  • GlobeNewswire

    Palisade Bio Provides Corporate Update and Reiterates Guidance

    – Company announces strategic streamlining of Board to align with the current state of clinical development and corporate vision – Advancement of PALI-2108 for the treatment of moderate-to-severe ulcerative colitis (UC) toward Phase 1 clinical study; first in human study on track to commence before year end Carlsbad, CA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serio

  • GlobeNewswire

    Correction Notice of Palisade Bio’s Press Release Announcing the Appointment of Clinical Advisory Board Members

    Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced a correction to its press release originally issued on February 8, 2024, announcing the appointments of Bruce Sands, MD, MS and Florian Rieder, MD to its Clinical Advisory Board (CAB). In the original press release, it was incorrectly stated that the